Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic / Pharmacodynamic Profile of VX-970 as a Single Agent in Combination With Carboplatin in Subjects With Advanced Solid Tumours

Next Previous
Search
Trial Profile

An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic / Pharmacodynamic Profile of VX-970 as a Single Agent in Combination With Carboplatin in Subjects With Advanced Solid Tumours

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Jul 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Berzosertib (Primary) ; Carboplatin
  • Indications Adenocarcinoma; Advanced breast cancer; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Malignant melanoma; Mesothelioma; Ovarian cancer; Solid tumours
  • Focus Adverse reactions; Pharmacogenomic; Proof of concept
  • Sponsors Vertex Pharmaceuticals

    • Most Recent Events

    • 22 Jun 2020 Results evaluating safety of VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors, published in the Journal of Clinical Oncology
    • 28 Feb 2019 Status changed from recruiting to completed.
    • 07 Jun 2016 Results (n=26) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top